All News

The Overpricing of Drugs (1.14.2022)

Save

Jack Cush, MD

Jan 14, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article

Hold Myophenolate or Not with COVID-19 Vaccination?

Save

Jack Cush, MD

Jan 13, 2022

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

Read Article

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Save

Jack Cush, MD

Jan 13, 2022

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Read Article

Sjogren_syndrome_salivary%20bx%282%29.jpg

Biologic Treatment of Primary Sjogrens with Ianalumab

Save

Jack Cush, MD

Jan 11, 2022

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

Read Article

BEAT LUPUS - Belimumab after Rituximab in SLE

Save

Jack Cush, MD

Jan 11, 2022

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).

Read Article

Best of 2021: Israel provides COVID vaccine answers for rheumatic disease patients

Save

David Liew, FRACP

Dec 28, 2021

The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br

Read Article

Best of 2021: FDA Approves Anifrolumab in SLE

Save

Jack Cush, MD

Dec 24, 2021

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

Read Article

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ

Links:

https://bit.ly/3JUEvMl

Dr. John Cush RheumNow ( View Tweet)

Jan 12, 2022

Good (long) open read review of Imaging in NPSLE (CNS lupus); mainly showing there is no SPECIFIC CNS imaging finding for NPSLE. Rather imaging (CT, MRI) done to r/o other pathology. PRES, PML, Vasculopathy, White matter lesions https://t.co/baUp6kjsKr

Links:

https://bit.ly/3JWhSHf

Dr. John Cush RheumNow ( View Tweet)

Jan 11, 2022

In Mouse Model of Lupus, when the gut microbiome of NZM2410 mice colonized w/ SFB, glomerulonephritis worsened & was assoc. w/ incr in TH17, MCP-1 and CXCL1, & more microbial abundance & biodiversity (dysbiosis) https://t.co/bLxrJZKTDZ

Links:

https://bit.ly/3r3g4DB

Dr. John Cush RheumNow ( View Tweet)

Jan 10, 2022

Links:

https://bit.ly/3tak08x

Dr. John Cush RheumNow ( View Tweet)

Jan 07, 2022

ASK CUSH ANYTHING! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/7q5sMQuIHj https://t.co/ksCCvzdxka

Links:

https://bit.ly/3mX32qi

Dr. John Cush RheumNow ( View Tweet)

Jan 05, 2022

Safety of COVID-19 Vaccines in Rheumatic Patients A multinational study shows that the use of COVID vaccination in rheumatic and musculoskeletal disease (I-RMD) is safe, well-tolerated with very rare serious adverse events (AEs). https://t.co/d30zbfa0f8 https://t.co/OM6GzAzTvQ

Links:

https://bit.ly/3zoZXEs

Dr. John Cush RheumNow ( View Tweet)

Jan 04, 2022

Best of 2021:Danish Cohort study of 5310 cutaneous LE/SLE pts between 1995-2014 (7-8 yrs F/U & 40.724 PYs) shows overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic & lung cancers https://t.co/Lgbe2hwtNj https://t.co/NzjM5LCuaX

Links:

https://bit.ly/3F26F4t

Dr. John Cush RheumNow ( View Tweet)

Jan 03, 2022

Best of 2021: Single center, 40 yr experience shows lupus psychosis to be rare. Among 709 SLE pts, 18 (2.5%) developed lupus psychosis. 2/3 remitted w/ antipsychotics & immunosuppressive Psychosis more likely w/ RNP and less likely w/ cardiolipin Abs. https://t.co/sKaZBqClyA https://t.co/i32kbIuEaX

Links:

https://bit.ly/3ENOFur

Dr. John Cush RheumNow ( View Tweet)

Jan 02, 2022

Links:

https://bit.ly/3zd251L

Dr. John Cush RheumNow ( View Tweet)

Dec 31, 2021

Best of 2021: Alveolar Hemorrhage and Mortality in Lupus Metanalysis of patients with DA), show this to be a rare and life-threatening complication of SLE, that is more apt to affect older, severe lupus patients with active infection. https://t.co/QvXiWKLTlm https://t.co/IFAS1loBId

Links:

https://bit.ly/32NqyOW

Dr. John Cush RheumNow ( View Tweet)

Dec 30, 2021

Danish Cohort study of 5310 cutaneous LE or SLE pts between 1995-2014 (7-8 yrs F/U and 40.724 PYs) shows an overall increased cancer risk for CLE (SIR 1.35)and SLE (1.45), esp a 3-4 fold increased risk for NHL, hematological, pancreatic and lung cancers https://t.co/MFPLG9ifGU

Links: